Compugen 경영진
경영진 기준 점검 4/4
Compugen CEO는 Eran Ophir, Mar2020 에 임명되었습니다 의 임기는 6.17 년입니다. 총 연간 보상은 $478.22K, 42.1% 급여 및 57.9% 보너스(회사 주식 및 옵션 포함)로 구성됩니다. 는 $32.65K 가치에 해당하는 회사 주식의 0.012% 직접 소유합니다. 경영진과 이사회의 평균 재임 기간은 2.2 년과 8.5 년입니다.
핵심 정보
Eran Ophir
최고경영자
US$478.2k
총 보수
| CEO 급여 비율 | 42.05% |
| CEO 재임 기간 | 6.2yrs |
| CEO 지분 보유율 | 0.01% |
| 경영진 평균 재임 기간 | 2.2yrs |
| 이사회 평균 재임 기간 | 8.5yrs |
최근 경영진 업데이트
Recent updates
내러티브 업데이트 • May 03
CGEN: Future Upside Will Rely On Sustained Long Term Execution Confidence
Analysts have maintained their $13.00 price target on Compugen, citing recent bullish initiation and supportive research as reasons to keep their outlook. This remains the case despite slight adjustments to assumptions for the discount rate, revenue growth, profit margin, and future P/E.내러티브 업데이트 • Apr 07
CGEN: Future Upside Will Depend On Sustained Long Term Earnings Potential
Analysts maintained their target for Compugen at $13.00, citing updated assumptions that now reflect a slightly higher discount rate, a modestly weaker revenue growth outlook, a small reduction in expected profit margin, and a very large projected future P/E multiple. Valuation Changes Fair Value: Target remains at $13.00, with no change from the prior estimate.내러티브 업데이트 • Mar 22
CGEN: Unchanged US$13 Fair Value Will Rely On Long Term Earnings
Analysts kept their $13.00 price target for Compugen unchanged, with only small tweaks to underlying inputs such as discount rate, revenue growth assumptions, profit margin, and very large future P/E expectations supporting the decision to maintain the prior valuation view. Valuation Changes Fair Value: $13.00 fair value is unchanged, signaling no revision to the overall price target level.내러티브 업데이트 • Mar 06
CGEN: Royalty Monetization And Immuno Oncology Pipeline Will Drive Future Upside
Analysts have reiterated a $13.00 price target on Compugen, citing updated assumptions that include a slightly higher discount rate, a shift to an 11% revenue contraction, a lower profit margin near 12%, and a very large forward P/E estimate as the basis for their current stance. What's in the News Compugen agreed with AstraZeneca to monetize a portion of its future royalties from rilvegostomig, amending their 2018 exclusive license agreement to support Compugen's balance sheet and immuno oncology pipeline (Key Developments).
새 내러티브 • Mar 03
Ovarian Trial Delays And Royalty Uncertainty Will Test This Long Runway Story
Catalysts About Compugen Compugen is a clinical stage immuno oncology company that uses a computational discovery engine to develop antibody based cancer therapies and out license assets to larger partners. What are the underlying business or industry changes driving this perspective?내러티브 업데이트 • Feb 20
CGEN: Royalty Sale And Oncology Pipeline Will Support Future Upside
Analysts have kept their price target for Compugen steady at $13.00, citing relatively unchanged fair value assumptions alongside small tweaks to the discount rate, very large projected revenue growth and expected profit margins, as well as an updated future P/E estimate. What's in the News Compugen and MedImmune Limited, part of the AstraZeneca Group, signed Amendment Number 4 to their March 30, 2018 license agreement covering rilvegostomig, updating the economic terms of Compugen's royalty interest (Key Developments).내러티브 업데이트 • Feb 06
CGEN: Royalty Monetization And Oncology Pipeline Will Drive Future Upside
Narrative Update on Compugen Analysts have kept their price target for Compugen steady at $13.00, citing only minor tweaks to assumptions around discount rate, very high projected revenue growth and profit margin that did not materially change their overall view. What's in the News Compugen agreed with AstraZeneca to monetize a portion of its future royalties from rilvegostomig, aiming to strengthen its balance sheet and support its immuno oncology pipeline (Key Developments).내러티브 업데이트 • Jan 23
CGEN: Future Upside Will Be Driven By Royalty Monetization Deal
Analysts have kept their fair value estimate for Compugen steady at $13.00, with only minor model tweaks to discount rates, revenue growth assumptions and future P/E, helping to refine rather than reset their overall price target view. What's in the News Compugen agreed with AstraZeneca to monetize a portion of its future royalties from the cancer drug candidate rilvegostomig, aiming to strengthen its balance sheet and support its immuno oncology pipeline (Key Developments).내러티브 업데이트 • Jan 09
CGEN: Future Upside Will Be Driven By Expanded Immuno Oncology Partnerships
Analysts have maintained their price target for Compugen at $13.00. They cite updated assumptions for discount rates, revenue growth, profit margins and a very large future P/E multiple as the main factors supporting this unchanged view.내러티브 업데이트 • Dec 14
CGEN: Future Revenue Trajectory Will Be Driven By Ongoing COM701 Program
Analysts have raised their price target on Compugen to 13.00 dollars from 13.00 dollars, citing sharply higher projected revenue growth, improved long term profit margins and a more favorable future earnings multiple, even after incorporating a slightly higher discount rate. What's in the News Pooled analysis of COM701 Phase 1 trials in 60 evaluable patients with platinum resistant ovarian cancer published as an abstract by the European Society of Medical Oncology, highlighting anti tumor activity and safety in heavily pre treated patients (ESMO abstract) Analysis details outcomes for patients deriving clinical benefit, including progression free survival data, and is based on data from prior COM701 studies in platinum resistant ovarian cancer (Company announcement) Additional year of follow up data on COM701 in platinum resistant ovarian cancer will be featured in an upcoming ESMO poster, expanding on the initial pooled findings (ESMO poster) Compugen estimates interim analysis results for the ongoing COM701 program to be available by year end 2026, guided by the anticipated enrollment rate (Company guidance) Valuation Changes Fair Value: Unchanged at 13.00 dollars per share, reflecting no revision to the base case price target.분석 기사 • Oct 07
There's No Escaping Compugen Ltd.'s (NASDAQ:CGEN) Muted Revenues Despite A 25% Share Price Rise
Compugen Ltd. ( NASDAQ:CGEN ) shares have had a really impressive month, gaining 25% after a shaky period beforehand...분석 기사 • Oct 02
Here's Why We're Not At All Concerned With Compugen's (NASDAQ:CGEN) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
내러티브 업데이트 • Aug 08
AI And Immunotherapy Advances Will Define Oncology's Future
Upward revisions to Compugen's revenue growth and net profit margin forecasts have driven a notable increase in its consensus analyst price target, which has risen from $5.50 to $6.25. What's in the News Compugen dosed the first patient in a global randomized sub-trial (MAIA-ovarian), evaluating its potential first-in-class anti-PVRIG antibody COM701 as maintenance therapy for relapsed platinum sensitive ovarian cancer.분석 기사 • May 25
Analysts Just Shaved Their Compugen Ltd. (NASDAQ:CGEN) Forecasts Dramatically
One thing we could say about the analysts on Compugen Ltd. ( NASDAQ:CGEN ) - they aren't optimistic, having just made a...분석 기사 • Apr 09
Is There An Opportunity With Compugen Ltd.'s (NASDAQ:CGEN) 33% Undervaluation?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Compugen fair value estimate is US$1.77 Current share price of...분석 기사 • Feb 26
Improved Revenues Required Before Compugen Ltd. (NASDAQ:CGEN) Shares Find Their Feet
You may think that with a price-to-sales (or "P/S") ratio of 2.9x Compugen Ltd. ( NASDAQ:CGEN ) is definitely a stock...
새 내러티브 • Jan 26
COM701 Trial Will Present Future Opportunities, But Competitive Risks Remain
Strategic advancements in drug development and partnerships could significantly bolster earnings and create opportunities in less competitive markets.분석 기사 • Aug 22
Investors Aren't Buying Compugen Ltd.'s (NASDAQ:CGEN) Revenues
You may think that with a price-to-sales (or "P/S") ratio of 4.1x Compugen Ltd. ( NASDAQ:CGEN ) is definitely a stock...분석 기사 • May 22
Analysts Have Been Trimming Their Compugen Ltd. (NASDAQ:CGEN) Price Target After Its Latest Report
Compugen Ltd. ( NASDAQ:CGEN ) just released its first-quarter report and things are looking bullish. The results were...분석 기사 • May 01
Why Investors Shouldn't Be Surprised By Compugen Ltd.'s (NASDAQ:CGEN) 25% Share Price Plunge
Compugen Ltd. ( NASDAQ:CGEN ) shareholders won't be pleased to see that the share price has had a very rough month...분석 기사 • Apr 05
Is Compugen Ltd. (NASDAQ:CGEN) Trading At A 36% Discount?
Key Insights Compugen's estimated fair value is US$3.61 based on 2 Stage Free Cash Flow to Equity Compugen's US$2.32...분석 기사 • Mar 08
Compugen Ltd.'s (NASDAQ:CGEN) Price Is Right But Growth Is Lacking After Shares Rocket 26%
Despite an already strong run, Compugen Ltd. ( NASDAQ:CGEN ) shares have been powering on, with a gain of 26% in the...분석 기사 • Feb 17
Compugen (NASDAQ:CGEN) Is In A Good Position To Deliver On Growth Plans
Just because a business does not make any money, does not mean that the stock will go down. For example, Compugen...분석 기사 • Oct 10
Will Compugen (NASDAQ:CGEN) Spend Its Cash Wisely?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...분석 기사 • Jun 22
Is Compugen (NASDAQ:CGEN) In A Good Position To Invest In Growth?
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...분석 기사 • Mar 04
Here's Why We're Not Too Worried About Compugen's (NASDAQ:CGEN) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, although...분석 기사 • Sep 21
Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Seeking Alpha • Sep 12
Compugen appoints Alberto Sessa as CFO
Clinical-stage cancer immunotherapy company Compugen (NASDAQ:CGEN) on Monday said it had appointed Alberto Sessa as its CFO. The appointment follows the departure of previous CFO Ari Krashin in May. Sessa will join CGEN on Nov. 1, 2022, the company said. According to CGEN, Sessa has more than 30 years of industry experience and most recently served as acting CFO at several startups in the high-tech industry. CGEN stock flat in mid-day trading.Seeking Alpha • Aug 24
Compugen gets Japanese patent for COM701, anti-PVRIG antibodies
Compugen (NASDAQ:CGEN) said that the Japan Patent Office granted a new composition of matter and use patent covering its anti-PVRIG, COM701 and backup anti-PVRIG antibodies. The Japanese patent No. 2017-562952 is expected to expire not before 2036. The company noted that in pre-clinical studies, blockade of PVRIG — a novel immune checkpoint — by COM701 has shown potent, reproducible enhancement of T cell activation, consistent with the desired mechanism of action of activating T cells in the tumor microenvironment to generate anti-tumor immune responses. CGEN +1.57% to $1.29 premarket Aug. 24Seeking Alpha • Aug 03
Compugen Q2 2022 Earnings Preview
Compugen (NASDAQ:CGEN) is scheduled to announce Q2 earnings results on Wednesday, August 3rd, after market close. The consensus EPS Estimate is -$0.11 (flat Y/Y) and the consensus Revenue Estimate is $0M Over the last 3 months, EPS estimates have seen 1 upward revision and 1 downward.분석 기사 • Jun 23
Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...분석 기사 • Mar 02
Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...분석 기사 • Nov 04
Here's Why We're Not Too Worried About Compugen's (NASDAQ:CGEN) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, although...분석 기사 • Aug 27
Shareholders Will Probably Not Have Any Issues With Compugen Ltd.'s (NASDAQ:CGEN) CEO Compensation
CEO Anat Cohen-Dayag has done a decent job of delivering relatively good performance at Compugen Ltd. ( NASDAQ:CGEN...CEO 보수 분석
| 날짜 | 총 보수 | 급여 | 회사 수익 |
|---|---|---|---|
| Dec 31 2025 | n/a | n/a | US$35m |
| Sep 30 2025 | n/a | n/a | -US$28m |
| Jun 30 2025 | n/a | n/a | -US$19m |
| Mar 31 2025 | n/a | n/a | -US$14m |
| Dec 31 2024 | US$478k | US$201k | -US$14m |
| Sep 30 2024 | n/a | n/a | US$2m |
| Jun 30 2024 | n/a | n/a | -US$10m |
| Mar 31 2024 | n/a | n/a | -US$17m |
| Dec 31 2023 | US$541k | US$196k | -US$19m |
보상 대 시장: Eran의 총 보수(USD478.22K)는 US 시장에서 비슷한 규모 기업의 평균(USD1.59M)보다 낮습니다.
보상과 수익: Eran의 보상은 지난 1년 동안 회사 실적과 일치했습니다.
CEO
Eran Ophir (47 yo)
6.2yrs
재임 기간
US$478,219
보수
Dr. Eran Ophir is CEO, President & Director of Compugen Ltd. from September 2025. Dr. Ophir was Senior Vice President of Research & Drug Discovery of Compugen Ltd.from March 2022 to 2023. Dr. Ophir was Vi...
리더십 팀
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| Executive Chair | 12.3yrs | US$1.24m | 0.11% $ 311.8k | |
| CEO, President & Director | 6.2yrs | US$478.22k | 0.012% $ 32.6k | |
| Chief Operating Officer | 1.3yrs | US$604.00k | 데이터 없음 | |
| Senior Vice President of Business Development | 8.3yrs | US$461.80k | 0.031% $ 84.3k | |
| Chief Medical Officer | 2.2yrs | US$592.99k | 0.024% $ 66.4k | |
| Chief Financial Officer | 1.8yrs | 데이터 없음 | 0.038% $ 101.9k | |
| General Counsel & Corporate Secretary | 7.3yrs | 데이터 없음 | 데이터 없음 | |
| Vice President of Human Resources | 19.3yrs | 데이터 없음 | 데이터 없음 | |
| Vice President Research and Discovery | no data | 데이터 없음 | 데이터 없음 | |
| Senior Vice President of Research & Discovery | less than a year | 데이터 없음 | 0.021% $ 56.0k |
2.2yrs
평균 재임 기간
48yo
평균 나이
경험이 풍부한 관리: CGEN의 경영진은 경험이 있음으로 간주됩니다(평균 재임 2.2 년).
이사회 구성원
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| Executive Chair | 12.3yrs | US$1.24m | 0.11% $ 311.8k | |
| CEO, President & Director | less than a year | US$478.22k | 0.012% $ 32.6k | |
| Member of Scientific Advisory Board | 5.7yrs | 데이터 없음 | 데이터 없음 | |
| Independent Director | 7.9yrs | 데이터 없음 | 0.013% $ 36.4k | |
| Member of Scientific Advisory Board | 12.8yrs | 데이터 없음 | 데이터 없음 | |
| Independent Director | 7.9yrs | 데이터 없음 | 0.012% $ 32.7k | |
| Independent Director | 7.9yrs | 데이터 없음 | 0.014% $ 38.3k | |
| Chairman of Scientific Advisory Board | 12.3yrs | 데이터 없음 | 데이터 없음 | |
| Member of Scientific Advisory Board | 12.8yrs | 데이터 없음 | 데이터 없음 | |
| Independent Director | 6.8yrs | 데이터 없음 | 0.011% $ 28.7k | |
| Member of Scientific Advisory Board | 12.8yrs | 데이터 없음 | 데이터 없음 | |
| Member of Scientific Advisory Board | 9.2yrs | 데이터 없음 | 데이터 없음 |
8.5yrs
평균 재임 기간
58yo
평균 나이
경험이 풍부한 이사회: CGEN의 이사회는 경험이 있음으로 간주됩니다(평균 재임 8.5 년).
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/12 22:44 |
| 종가 | 2026/05/12 00:00 |
| 수익 | 2025/12/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Compugen Ltd.는 10명의 분석가가 다루고 있습니다. 이 중 5명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Ling Wang | Chardan Capital Markets, LLC |
| Michael King | Citizens JMP Securities, LLC |
| Swayampakula Ramakanth | H.C. Wainwright & Co. |